Unfavorable Intermediate (UFI)-Risk Prostate Cancer Testing

Dr. Steve Shak, Chief Medical Officer at Exact Sciences discusses the publication of new analyses of two clinical studies that demonstrate for the first time the value of the Oncotype DX Genomic Prostate Score® (GPS™) test in guiding treatment plans in patients with unfavorable intermediate (UFI)-risk prostate cancer. The study, published in “Urology”, validates the GPS test as a strong independent predictor of critical endpoints in UFI-risk prostate cancer patients, suggesting its benefit in personalizing and improving treatment decisions. 

Dr. Steve Shak is the Chief Medical Officer for Exact Sciences. Joining the company in 2019 upon the closing of the Genomic Health / Exact Sciences combination, his key responsibilities include leading strategy for the company’s clinical development plans, building relationships with key leaders and institutions in the cancer community, and ensuring the voice of patients and physicians are heard at all levels of the organization. Before serving as Chief Medical Officer, he was the Co-Founder, Chief Medical Officer, and Chief Scientific Officer at Genomic Health, driving Oncotype DX assay development in breast, prostate and colon cancer. Before then, he was the Research Director and Staff Clinical Scientist at Genentech, leading the clinical team in the development of the targeted breast cancer drug Herceptin®, and the research team in the discovery of the cystic fibrosis drug Pulmozyme®. He also taught as an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Dr. Shak received his medical degree from New York University School of Medicine and his formal post-doctoral training at Bellevue Hospital and the University of California, San Francisco. He has a bachelor’s degree from Amherst College in Massachusetts.